Testagen is a synthetic peptide built from four amino acids: lysine, glutamic acid, aspartic acid and glycine. A peptide is a short chain of amino acids, and a four-amino-acid chain is called a tetrapeptide. Testagen has no parent protein: the sequence was designed from the amino acid composition of pituitary cytomedins, peptide complexes extracted from the gland [2]. It belongs to a group of short peptides studied together: Epithalon and Pinealon appear with it in the 2011 nuclear-uptake study, and all three appear in the 2013 histone study [6][7].
Kuznik's group at Chita State Medical Academy reported the tetrapeptide in 2008. The paper says it was synthesized from the amino acid composition of pituitary cytomedins, peptide complexes extracted from the gland [2]. The group gave it for 40 days to chickens whose pituitary had been removed in the first days of life, and thyrotropic hormone, thyroid hormone levels and thyroid structure recovered [2]. In 2011 a team from Kharkiv and Belgorod studied a dietary supplement sold as Testagen, which the paper describes as a peptide complex of lysine, glutamic acid, aspartic acid and glycine [1]. That year Fedoreyeva, Khavinson and colleagues also showed that the peptide enters the nucleus of human cells and binds DNA with sequence preferences [6].
The research potential is narrow: the peptide is studied for thyroid, thymus and testosterone effects [1][2][4], and the cell work suggests it can bind DNA and histones [6][7]. Most of the evidence cited here comes from birds and cells rather than from mammals. As of October 2026, Testagen has no FDA-approved drug product and one published 30-day human study [1][13]. It does not appear on FDA's May 14, 2026 list of bulk substances nominated for 503A compounding [11], and neither the WADA nor the NCAA list names it [9][10].
Key takeaways
- Testagen is a synthetic tetrapeptide designed from pituitary peptide extracts and studied for thyroid, thymus and testosterone effects [1][2][4].
- Its human evidence is one 30-day study of 36 men: total testosterone rose from 7.1 to 9.8 nanomoles per liter, still below the 11 nanomoles per liter cutoff used to define deficiency, and the paper does not describe randomization or blinding [1].
- WADA's 2026 list does not name it, but its S2 class covers peptide hormones and testosterone-stimulating peptides in males, and the NCAA class language reaches related substances too [9][10].
How it works
A short peptide that reaches the cell nucleus
Testagen reaches the cell nucleus, which points to an intracellular route rather than a receptor on the surface. A receptor is a protein that a signal molecule docks with to start a response, and most peptide hormones act that way. Direct evidence for nuclear entry came from fluorescence microscopy: Fedoreyeva and colleagues attached a fluorescent dye to the peptide and watched where it went in HeLa cells, a human cervical cancer cell line used as a laboratory stand-in [6]. Fluorescence appeared in the cytoplasm, in the nucleus and in the nucleolus, the structure inside the nucleus where ribosomes are assembled [6].
The same study tested whether the peptide binds DNA. The workers mixed it with short fluorescently labeled DNA strands and measured how much the label dimmed, a technique called fluorescence quenching that reports binding [6]. Testagen quenched CAG-rich strands more than other sequences, and the study reported that the peptides could distinguish methylated from unmethylated cytosine, a chemical mark that cells use to switch genes off [6]. Binding was sequence-dependent, which suggests a specific interaction rather than a general electrostatic attraction. The experiment was done in a test tube, so it shows affinity and preference, not what the peptide does to a living cell's genes [6].
Histones and the chromatin hypothesis
DNA in a cell is wrapped around histones, proteins that package it into chromatin, the material of chromosomes. Fedoreyeva's group next labeled wheat histones H1, H2B, H3 and H4 and measured Testagen binding by the same quenching method [7]. The peptide bound all four histones, and binding depended on the histone, on the peptide's primary structure and on the DNA present [7]. The authors proposed that short peptides bound to histone tails could act as epigenetic regulators, meaning they could change which genes are read without changing the DNA code [7].
The histone experiment carries a large caveat. Wheat histones are plant proteins, the authors found no homologous amino acid sequences in wheat core histones, and they suggested that the peptides bind regions with a specific conformation rather than a conserved sequence [7]. No human chromatin, no intact cell and no transcription readout were tested. The papers name no receptor for Testagen, and the chromatin model remains a hypothesis rather than a demonstrated mechanism [6][7].
The pituitary, thyroid and thymus experiments
Much of the animal evidence comes from birds whose pituitary gland was surgically removed, a procedure called hypophysectomy. The pituitary sits at the base of the brain and releases thyrotropic hormone, or TSH, which tells the thyroid gland to make the hormones T3 and T4. Removing it produces secondary hypothyroidism: the thyroid atrophies, hormone levels fall and follicle structure breaks down. In the 2008 experiment, 40 days of either tetrapeptide raised TSH and thyroid hormone concentrations and restored thyroid structure in neonatally hypophysectomized chickens [2].
A 2011 follow-up compared young chickens with old hens and found the same direction of effect, weaker in the older birds [3]. The thymus work extended the target to immune tissue: after neonatal hypophysectomy the thymus showed its most pronounced changes, and both peptides promoted recovery of its structure, with Testagen acting more strongly than the posterior-pituitary peptide [4]. A 2010 report from the same group added that the peptides prevented thyroid atrophy and normalized immune and hemostatic parameters, meaning clotting and clot breakdown [5]. The abstracts do not explain how a peptide raises TSH after the pituitary has been removed [2][3].
Testosterone, the prostate and the missing target
The testosterone claim rests on the 2011 human study. Total testosterone rose from 7.1 to 9.8 nanomoles per liter in the treated group, while the control group moved from 7.1 to 7.5 [1]. Luteinizing hormone and follicle-stimulating hormone, the pituitary signals that tell the testes to make testosterone, did not rise: luteinizing hormone fell from 3.71 to 3.08 nanograms per milliliter and follicle-stimulating hormone from 2.95 to 2.21 [1]. A rise in testosterone without a rise in those signals suggests the effect is not driven by increased pituitary signaling, although the study measured hormones at only two points and cannot locate the effect [1].
In the prostate, the symptom score and the leukocyte count in prostatic fluid fell further in the treated group than in the control group [1]. The design cannot separate a peptide effect from the two drugs given to both groups or from the lack of a placebo. The published mechanism work names no receptor, enzyme or binding partner for Testagen [6][7].
What has been studied in humans
One human study of Testagen has been published. It appeared in 2011 in Problems of Endocrine Pathology, a Ukrainian endocrinology journal, and it enrolled 36 men aged 38 to 49 with chronic abacterial prostatitis category IIIA and compensated age-related androgen deficiency [1]. Category IIIA means inflammatory chronic pelvic pain syndrome without a bacterial cause. All 36 received tamsulosin, an alpha-1 blocker that relaxes the prostate and bladder neck, and a diclofenac rectal suppository [1]. Twenty men also received Testagen for 30 days, and 16 formed the control group [1].
At one month, mean urinary flow in the treated group rose from 13.5 to 17.4 milliliters per second, and the time to peak flow fell from 6.4 to 4.4; the control group's mean flow reached 15.1 milliliters per second [1]. The NIH Chronic Prostatitis Symptom Index, a standard symptom questionnaire, fell from 16.1 to 9.8 with Testagen and to 11.5 with standard therapy alone [1]. The table lists leukocytes in prostatic secretions falling from 28.2 to 15.4 per field of view in the treated group and from 28.2 to 25.6 in controls [1]. Pollakiuria, nocturia and stranguria, the urinary symptoms the paper tracked, resolved in 75, 70 and 65 percent of treated men against 62, 44 and 62 percent of controls [1].
The hormone result is the part that made the peptide's reputation. Total testosterone rose from 7.1 to 9.8 nanomoles per liter in the treated group (p<0.05) and from 7.1 to 7.5 in controls [1]. Luteinizing hormone fell from 3.71 to 3.08 nanograms per milliliter and follicle-stimulating hormone from 2.95 to 2.21, neither marked as significant [1]. Even after treatment, the mean testosterone level stayed below the 11 nanomoles per liter threshold the authors used to define deficiency [1].
The study has serious limits. The paper describes two groups that were statistically similar in age and symptom scores but does not state randomization, blinding or a sample-size calculation, and it does not report adverse events or discontinuations [1]. It measured hormones at baseline and 30 days only, did not measure the peptide in blood, and tested one commercial supplement rather than the pure peptide [1]. A ClinicalTrials.gov search on October 23, 2026 returned one record using the name Testagen, a transdermal testosterone product rather than the peptide [12].
Doses studied in human trials
As of October 2026, Testagen remains a research peptide with no FDA-approved drug product and a single published human study [1][13]. Regimens below are those reported in the cited human trials.
Two 0.100 mg capsules with food twice daily for 30 days (0.4 mg per day), added to tamsulosin and a 100 mg diclofenac rectal suppository
36 men aged 38 to 49 (mean 44.8) with compensated age-related androgen deficiency and chronic abacterial prostatitis category IIIA
Lab and animal studies
The animal work cited here is avian and comes from one laboratory. The 2008 and 2011 thyroid studies both gave peptide for 40 days to hypophysectomized chickens [2][3]. In the 2008 study, both tetrapeptides raised TSH and thyroid hormones and restored thyroid structure; the 2011 study reported that treatment reduced the hormonal and structural changes, less so in old hens [2][3]. The 2013 thymus study added a second organ, with the anterior-pituitary peptide outperforming the posterior-pituitary one [4].
The 2010 report described the untreated hypophysectomized bird in more detail: enlarged thyroid follicles, colloid accumulation, an increased nucleus-to-cytoplasm ratio in thyrocytes, atrophied interfollicular epithelium, depressed immunity, hypercoagulation and depressed fibrinolysis [5]. The peptides prevented the thyroid changes and normalized the immune and clotting measures [5]. These are broad claims from a short abstract, and the paper does not report which immune or clotting tests moved, by how much.
The cell work is more precise but further from a living animal. In HeLa cells the peptide reached the nucleus and nucleolus, and in test tubes it bound CAG-rich DNA and all four wheat histones [6][7]. The authors suggest an epigenetic route in which short peptides dock on chromatin and change gene activity [7]. The papers name no receptor for the peptide [6][7]. None of the preclinical studies cited here is mammalian, none reports toxicology, and none reports a pharmacokinetic measurement; the doses used in the bird experiments are not in the abstracts [2][3][4].
The 2025 copper study is a different kind of science. It measured how the peptide adsorbs to a copper electrode in 0.9 percent sodium chloride solution, fitted the data to an adsorption isotherm, and computed the electronic properties of the peptide-metal interaction [8]. The result is an effective corrosion inhibitor in that test and evidence that the peptide binds copper at the surface. The paper also proposes that the peptide can attach to copper ions and deplete copper in the body, a question the paper did not test [8].
Research in detail
Two-group comparison at a urology clinic in Kharkiv and a surgical clinic in Belgorod; randomization and blinding are not described · 36 men aged 38 to 49 (mean 44.8) with compensated age-related androgen deficiency and chronic abacterial prostatitis category IIIA
Mean urinary flow rose from 13.5 to 17.4 milliliters per second, the NIH-CPSI score fell from 16.1 to 9.8, prostate-secretion leukocytes fell from 28.2 to 15.4 per field, and total testosterone rose from 7.1 to 9.8 nanomoles per liter (p<0.05); the control group reached 15.1 milliliters per second, 11.5 and 25.6, with testosterone at 7.5 nanomoles per liter.
Evidence scope: Full text reviewed; randomization and blinding are not described; 30 days, 20 versus 16 men, a supplement formulation, no adverse-event analysis, and mean testosterone stayed below the 11 nanomoles per liter cutoff used to define deficiency.
Animal experiment with 40 days of peptide administration · Neonatally hypophysectomized chickens
Both tetrapeptides raised thyrotropic hormone and thyroid hormone concentrations and restored thyroid gland structure.
Evidence scope: Abstract only; group sizes and doses are not reported, and the model removes the pituitary, so the route to a TSH rise is unexplained.
Animal experiment in young chickens and old hens given peptide for 40 days · Chickens hypophysectomized at five days of age and old hens
The peptides significantly reduced hypophysectomy-induced hormonal and structural changes; the effect on thyrotropic hormone and thyroid hormones was less pronounced in old hens.
Evidence scope: Abstract only; doses and group sizes are not reported, and the age comparison is descriptive.
Histological study in hypophysectomized birds of different ages · Chicks and old birds after hypophysectomy
Both peptides promoted recovery of thymic structure at every age, and the anterior-pituitary peptide had the stronger effect than the posterior-pituitary peptide.
Evidence scope: Abstract only; no functional immune measurements, doses or group sizes.
In vitro fluorescence microscopy and DNA-binding assay · HeLa human cervical cancer cells and synthetic deoxyribooligonucleotides
Fluorescein-labeled Testagen entered the cytoplasm, nucleus and nucleolus; it bound CAG-containing DNA preferentially, and the study reported that the peptides could distinguish methylated from unmethylated cytosine.
Evidence scope: Abstract reviewed; full text not read. Cell-line and test-tube binding only; no transcriptional or phenotypic readout, and the reported constants are Stern-Volmer quenching constants rather than dissociation constants.
In vitro fluorescence-quenching binding assay · FITC-labeled wheat histones H1, H2B, H3 and H4, and their DNA complexes
Testagen bound all four histones, with site specificity that depended on the peptide's primary structure; the authors proposed chromatin-level epigenetic regulation.
Evidence scope: Abstract reviewed; full text not read. Wheat histones rather than human chromatin, no cells and no functional transcription assay.
Electrochemical, spectroscopic and computational adsorption study · Copper electrodes in 0.9 percent sodium chloride solution with 5 to 20 milligrams per liter of peptide
At 20 milligrams per liter the peptide inhibited copper corrosion by about 86 percent through spontaneous mixed physical and chemical adsorption, forming peptide-copper complexes at the surface.
Evidence scope: Full text reviewed. A corrosion-chemistry experiment with no biological component; its suggestion that the peptide could deplete copper in the body was not tested.
History and where it stands today
Testagen moved from chicken thyroid experiments to a small human supplement study, and the research has since split between chromatin biology and materials chemistry.
- 2008A report described how 40 days of treatment raised TSH and thyroid hormones and restored thyroid structure in hypophysectomized chickens [2].
- 2010The same group reported that the peptides prevented thyroid atrophy and normalized immune and hemostatic parameters in hypophysectomized birds [5].
- 2011A team from Kharkiv and Belgorod added a Testagen supplement to standard therapy in 36 men with chronic abacterial prostatitis and age-related androgen deficiency, and reported better urinary flow, lower prostate inflammation and higher total testosterone after 30 days [1].
- 2011Fedoreyeva, Khavinson and colleagues showed nuclear and nucleolar uptake of the peptide in HeLa cells and sequence-specific DNA binding [6].
- 2013Two reports followed: the thymus study found stronger recovery with Testagen than with the posterior-pituitary peptide, and the histone study showed binding to H1, H2B, H3 and H4 [4][7].
- 2025A physical-chemistry group reported that the peptide adsorbs to copper in salt water and inhibits copper corrosion by about 86 percent at 20 milligrams per liter [8].
- October 2026As of October 2026, Testagen has no FDA-approved drug product, one human study and no registered trial [1][12][13]. It is absent from FDA's May 2026 nominated 503A list [11], WADA does not name it [9], and the NCAA list does not name it either [10].
How it compares with related peptides
Epithalon is the name used in the peptide literature for the posterior-pituitary peptide in the thyroid and thymus experiments [2][4][6]. Both are four amino acids long, and in these experiments both were synthesized from pituitary lobe extracts, with the posterior peptide standing in as the comparator to Testagen from the anterior lobe [2][3]. In the thymus study Testagen produced the stronger recovery [4].
Pinealon is a tripeptide, one amino acid shorter, and it appeared with Testagen in the same 2011 nuclear-uptake study [6]. Both peptides entered HeLa nuclei and nucleoli, and both bound DNA, with the same preference for CAG-containing sequences in that assay [6].
Bronchogen is a tetrapeptide that also appeared in the DNA-binding and histone experiments [6][7]. In the DNA-binding work it preferred CTG-containing sequences while Testagen preferred CAG-containing ones, which shows how changes in peptide structure shift sequence preference [6]. Both have been studied for binding to DNA and histones [6][7].
Side effects and safety signals
The safety record is limited: one 30-day supplement study in 36 men and a set of bird experiments that did not report toxicology.
- The 2011 human paper does not report adverse events, discontinuations or a safety analysis; it lists clinical and laboratory outcomes [1].
- Human exposure is limited to the 30-day regimen in 20 men, given as a supplement alongside two drugs; the study did not test longer use, larger amounts or use without those drugs [1].
- The animal abstracts report no toxicology: no dose-ranging, organ histology outside the target tissue, blood counts or mortality data appear in them [2][3][4].
- Oral absorption is unmeasured: the human study gave capsules and never measured the peptide in blood, so the amount reaching the testis, thyroid or thymus is unknown [1].
- Metal binding is a laboratory finding with an open safety question: the 2025 study shows the peptide forms complexes with copper at a metal surface, and the paper proposes that it can attach to copper ions and deplete copper in the body, a possibility the study did not test [8].
- The paper does not document identity and purity: the 2011 product was a dietary supplement, and the report gives no certificate of analysis for the capsules [1]. Independent COA testing is the usual check on identity and purity for a research peptide.
The future: what's next for Testagen
The obvious next experiment is a randomized trial. A blinded, placebo-controlled add-on study with total testosterone as the primary endpoint, a longer treatment period and a pharmacokinetic arm would separate a real hormone effect from the noise of a 36-man study that does not describe blinding [1][12]. No such trial is registered: a ClinicalTrials.gov search on October 23, 2026 returned one record, a transdermal testosterone product, and no trial of the peptide [12].
The regulatory picture is limited. A Drugs@FDA search on October 23, 2026 returned no approved product containing Testagen [13], and the peptide does not appear on the agency's May 14, 2026 list of bulk substances nominated for 503A compounding, so it is not part of that review [11]. WADA's 2026 list does not name it, but S2 covers peptide hormones and prohibits substances with a similar chemical structure or similar biological effect, and S2.2.1 specifically lists testosterone-stimulating peptides in males [9]. The NCAA's 2026-27 list does not name it either; its peptide-hormone class bans chemically or pharmacologically related substances [10].
The mechanistic question is the chromatin model. Testing it needs human cells, intact chromatin and a transcription readout, none of which the cited experiments used [6][7]. A binding partner would make the peptide easier to study, and a measure of oral absorption would tell researchers whether the capsule ever reaches the tissues the bird work examined [1]. The copper result adds a separate question about metal binding that the cited experiments did not address [8].
- Whether the testosterone rise reproduces in a randomized, blinded trial, and whether it can lift mean levels above the 11 nanomoles per liter deficiency threshold [1].
- Which protein or DNA structure the peptide actually binds in human cells, and whether histone binding explains any of its effects [6][7].
- How much peptide reaches the blood, testis or thyroid after oral intake, since the cited study reported no pharmacokinetic measurement [1].
- Whether the thyroid and thymus findings in hypophysectomized birds have any counterpart in mammals or in humans with an intact pituitary [2][3][4].
- Whether the copper complexes seen at a metal surface form in the body and what they would do there [8].
